5-Amino-1MQ Research: What the Studies Actually Show

5-Amino-1MQ — 5-amino-1-methylquinolinium, written 5A1MQ or 5-AMQ in the primary literature — is one of the few research compounds in the metabolism space that is not a peptide at all. It is a small, positively charged aromatic molecule designed in a university laboratory to switch off a single enzyme: nicotinamide N-methyltransferase, or NNMT. Most of what circulates about it online is extrapolation from mouse studies. This summary stays with the papers. It covers how the inhibitor was designed, what it does to NAD⁺ and methyl-donor chemistry inside cultured cells, what rodent models have reported, and where the evidence stops. For the cofactor at the centre of the story, see our explainer on what NAD⁺ is.

Research-use-only context. This article summarizes published third-party scientific literature — the large majority of it conducted in cultured cells or animal models. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. American Peptides products are sold strictly for in vitro laboratory research and are not for human or veterinary use.

What 5-Amino-1MQ is

5-Amino-1MQ is a quinolinium: a two-ring, nitrogen-containing aromatic system in which the ring nitrogen carries a methyl group and a permanent positive charge, with an amino group at position 5. It is a small molecule of roughly 160 daltons, not a chain of amino acids. It has no peptide bonds, no sequence and no receptor target in the usual sense. It was built to bind the substrate pocket of one enzyme and sit there.

That enzyme, NNMT, is a cytosolic methyltransferase. Reviews describe its core reaction in the same terms: NNMT takes a methyl group from S-adenosyl methionine (SAM), the cell’s universal methyl donor, and transfers it to nicotinamide, yielding S-adenosyl homocysteine (SAH) and 1-methylnicotinamide (1-MNA).^4,5 Two consequences follow from that single step. First, nicotinamide is the entry substrate for the NAD⁺ salvage pathway, so methylating it removes a molecule that would otherwise be recycled into NAD⁺. Second, every methylation consumes a SAM, which is the same methyl donor that histone and DNA methyltransferases depend on. A 2021 review in Molecular Metabolism therefore places NNMT “at the crossroads” of cellular energy metabolism and epigenetic regulation, directly linking one-carbon metabolism, a cell’s methylation balance and its NAD⁺ levels.⁵

NNMT was originally characterised as a liver enzyme for clearing excess vitamin B3, and a 2017 review in Trends in Endocrinology & Metabolism is titled around exactly that point: the enzyme is “more than a vitamin B3 clearance enzyme,” with implicated roles in adipose, liver and cancer-cell metabolism through its consumption of methyl donors and generation of active metabolites.⁴ The adipose connection is older than the inhibitor. A 2009 study in Atherosclerosis showed that 3T3-L1 adipocytes and human and murine adipose-tissue explants express high amounts of enzymatically active NNMT, that expression rises as the cells differentiate, and that the reaction’s downstream product homocysteine is released from adipocytes in culture.⁷ That observation is one reason fat cells became the test bed for NNMT inhibitors.

What the research reports

Enzyme chemistry and inhibitor design

The 5-Amino-1MQ story begins with an assay. In 2017 the Watowich laboratory at the University of Texas Medical Branch published a noncoupled fluorescent method that monitors NNMT activity in real time by detecting a methylated quinolinium product directly.³ The same paper worked out the kinetic mechanism: a random bireactant model in which either substrate can bind the free enzyme, but each binds roughly 20-fold more tightly once the other is already in place.³ That is the mechanistic logic behind a product-like inhibitor — a methylated quinolinium that occupies the nicotinamide pocket mimics what the enzyme has just made.

The medicinal chemistry followed in the Journal of Medicinal Chemistry. Screening N-methylated quinolinium, isoquinolinium, pyridinium and benzimidazolium/benzothiazolium analogues produced a greater than 1,000-fold range of activity, and quinoliniums emerged as the most promising scaffold, with the best compounds inhibiting NNMT at very low micromolar concentrations (IC₅₀ around 1 µM).¹ Computational docking of the analogues into the nicotinamide-binding site produced a robust correlation between predicted interaction scores and measured IC₅₀ values, and the predicted binding orientation identified the ring features that drive the protein–ligand contacts.¹ A follow-up in Biochemical Pharmacology then showed why the 5-amino substitution matters: methylquinolinium scaffolds carrying a primary amine displayed high permeability across membranes in both parallel artificial membrane and Caco-2 cell assays, by passive and active transport.² A permanently charged molecule normally struggles to enter cells; this was the design problem the amino group solved.

In-vitro findings in cultured adipocytes

The 2018 Biochemical Pharmacology paper is the central in-vitro reference. In cultured adipocytes, the NNMT inhibitors reduced intracellular 1-MNA — the enzyme’s product, so the expected pharmacodynamic marker — and increased intracellular NAD⁺ and SAM, the two metabolites the enzyme would otherwise have consumed.² The same cells showed suppressed lipogenesis.² The authors framed increased flux of NAD⁺ and SAM as the candidate mechanism of action, and that framing is what most later discussion of 5-Amino-1MQ rests on.² It is worth being precise about what was measured: an inhibitor applied to a cell line shifted three metabolite pools in the direction the reaction scheme predicts. That is a clean biochemical result, and it is a cell-culture result.

The muscle work extends the cell biology in a different direction. A 2019 study, again from the UTMB group, reported that an NNMT inhibitor promoted differentiation of C2C12 myoblasts in vitro, with accompanying shifts in the cellular NAD⁺/NADH redox state.⁶ The rationale the authors give connects NNMT to sirtuin 1, an NAD⁺-dependent deacetylase, via the salvage pathway.⁶

Animal-model findings as reported

Three rodent papers anchor the in-vivo literature, all from the same group. The 2018 paper exposed diet-induced obese mice on a high-fat diet to a potent NNMT inhibitor systemically and reported lower body weight, reduced white adipose mass, smaller adipocytes and lower plasma total cholesterol relative to control animals; total food intake did not change.² The 2019 study worked in 24-month-old mice after an induced injury to the tibialis anterior muscle and reported elevated muscle stem-cell proliferation and fusion, roughly two-fold greater myofibre cross-sectional area, a shift toward larger fibres, and about 70% higher peak torque in the inhibitor-exposed animals compared with controls.⁶ A 2024 study in Diabetes Obes Metab returned to diet-induced obese mice, reported that 5A1MQ limited body-weight and fat-mass gains, improved glucose tolerance and insulin sensitivity, and reduced liver steatosis and triglyceride content, and documented that the compound reached adipose, muscle and liver tissue after systemic exposure.⁸

These are mouse findings. Body-composition results in a diet-induced rodent model are a standard pharmacology readout and say nothing about any other species or setting. The 2024 paper also carries a declared conflict of interest: its senior authors founded or are employed by the company developing NNMT inhibitors commercially.⁸ That does not invalidate the data, but it is context a reader should have.

Selectivity and off-target questions

Selectivity is the strongest part of the 5-Amino-1MQ characterisation and also where its limits are clearest. The 2018 paper tested the methylquinolinium series against structurally related SAM-dependent methyltransferases and against the enzymes of the NAD⁺ salvage pathway and reported no inhibition of either class.² That is an important control, because a compound that raised NAD⁺ by blocking NNMT but also hit other methyltransferases would confound every downstream interpretation. What the published panels do not cover is the broader proteome: a positively charged aromatic cation can in principle interact with other cationic-ligand binding sites, and no wide off-target screen for 5-Amino-1MQ has appeared in the peer-reviewed literature we located. The reviews also stress that NNMT biology is tissue-specific — expression in liver, adipose and tumour cells behaves differently — so inhibiting the enzyme everywhere at once is not the same experiment as knocking it down in one tissue.^4,5

The human-evidence gap

There are no published controlled human studies of 5-Amino-1MQ. None. The compound is not approved by the FDA or any other regulator for any purpose, and it is not in a registered clinical programme that has reported results. Every outcome-type finding summarised above comes from cultured cells or from mice, and the large majority comes from a single academic group and its spin-out company. Independent laboratories have studied NNMT biology extensively — the 2009 adipose work and the two reviews cited here are from unrelated groups — but independent replication of the 5-Amino-1MQ animal findings specifically is thin. Reviewers who cover NNMT as a target also discuss the current limitations of existing NNMT inhibitors, which is a reminder of how early this chemistry is.⁵

The gap matters mechanistically as well as regulatorily. Because NNMT sits between NAD⁺ salvage and the methylation economy, blocking it changes two things at once, and nobody has shown in a human tissue what the net effect of that trade is. Research-grade 5-Amino-1MQ exists to let laboratories ask that question in cells and animals — it is not evidence that the question has been answered.

The takeaway

5-Amino-1MQ is a well-defined chemical tool: a membrane-permeable, product-mimicking quinolinium that inhibits NNMT in the low-micromolar range, spares related methyltransferases and salvage-pathway enzymes in the published panels, and raises NAD⁺ and SAM while lowering 1-MNA in cultured adipocytes. The rodent literature on body composition and aged-muscle regeneration is consistent with that mechanism, comes almost entirely from one group, and has no human counterpart. It is not a peptide, and it should not be read through the lens of peptide pharmacology. American Peptides supplies 5-Amino-1MQ strictly for in vitro research; formula and handling specifications are on the product page.

Frequently Asked Questions

Is 5-Amino-1MQ a peptide?

No. It is a small-molecule quinolinium cation of roughly 160 daltons with no amino-acid sequence or peptide bonds. It is grouped with research peptides only because it is studied in the same metabolism and NAD⁺ context.

What does NNMT actually do?

NNMT transfers a methyl group from SAM to nicotinamide, producing 1-methylnicotinamide and SAH. That one reaction removes a precursor from the NAD⁺ salvage pathway and consumes a methyl donor, which is why reviews describe it as a link between energy metabolism and methylation balance.

What did the adipocyte studies measure?

In cultured adipocytes, methylquinolinium NNMT inhibitors reduced intracellular 1-MNA, raised intracellular NAD⁺ and SAM, and suppressed lipogenesis. These are cell-culture measurements of metabolite pools, not outcomes in any organism.

Is 5-Amino-1MQ approved by the FDA?

No. It is a preclinical research compound with no published human studies and is not approved for any use. American Peptides supplies it strictly for in vitro research.

Citations

1. Neelakantan H, et al. “Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase.” J Med Chem. 2017;60(12):5015–5028. PubMed: PMID 28548833
2. Neelakantan H, et al. “Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.” Biochem Pharmacol. 2018;147:141–152. PubMed: PMID 29155147
3. Neelakantan H, et al. “Noncoupled Fluorescent Assay for Direct Real-Time Monitoring of Nicotinamide N-Methyltransferase Activity.” Biochemistry. 2017;56(6):824–832. PubMed: PMID 28121423
4. Pissios P. “Nicotinamide N-Methyltransferase: More Than a Vitamin B3 Clearance Enzyme.” Trends Endocrinol Metab. 2017;28(5):340–353. PubMed: PMID 28291578
5. Roberti A, et al. “Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation.” Mol Metab. 2021;45:101165. PubMed: PMID 33453420
6. Neelakantan H, et al. “Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle.” Biochem Pharmacol. 2019;163:481–492. PubMed: PMID 30753815
7. Riederer M, et al. “Adipose tissue as a source of nicotinamide N-methyltransferase and homocysteine.” Atherosclerosis. 2009;204(2):412–417. PubMed: PMID 18996527
8. Babula JJ, et al. “Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction.” Diabetes Obes Metab. 2024;26(11):5272–5282. PubMed: PMID 39161060

Related reading

• What Is NAD+? A Science Explainer
• MOTS-c Research: What the Studies Show
• The Biology of Metabolism and Appetite

This article is for laboratory research reference only. American Peptides products are sold strictly for in vitro research. Not for human consumption.

---

Compliance Notice: American Peptides products are sold strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution’s safety protocols and applicable laws.